Morgan Stanley’s Mustang Bio MBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $86 | Sell |
118
-35
| -23% | -$33 | ﹤0.01% | 7830 |
|
|
2025
Q4 | $150 | Sell |
153
-150
| -50% | -$198 | ﹤0.01% | 7661 |
|
|
2025
Q3 | $461 | Buy |
303
+66
| +28% | +$117 | ﹤0.01% | 7506 |
|
|
2025
Q2 | $226 | Sell |
237
-61
| -20% | -$74 | ﹤0.01% | 7556 |
|
|
2025
Q1 | $373 | Buy |
298
+62
| +26% | +$236 | ﹤0.01% | 7409 |
|
|
2024
Q4 | $2.08K | Buy |
236
+58
| +33% | +$640 | ﹤0.01% | 7192 |
|
|
2024
Q3 | $2.09K | Sell |
178
-1
| -0.6% | -$17 | ﹤0.01% | 7127 |
|
|
2024
Q2 | $4.24K | Sell |
179
-54
| -23% | -$1.03K | ﹤0.01% | 6890 |
|
|
2024
Q1 | $12.1K | Sell |
233
-238
| -51% | -$15.1K | ﹤0.01% | 6638 |
|
|
2023
Q4 | $31.8K | Buy |
471
+232
| +97% | +$18.4K | ﹤0.01% | 6506 |
|
|
2023
Q3 | $24.8K | Buy |
239
+10
| +4% | +$1.94K | ﹤0.01% | 6422 |
|
|
2023
Q2 | $71.1K | Buy |
229
+26
| +13% | +$6.53K | ﹤0.01% | 6078 |
|
|
2023
Q1 | $55.8K | Sell |
203
-165
| -45% | -$67.6K | ﹤0.01% | 6242 |
|
|
2022
Q4 | $109K | Sell |
368
-27
| -7% | -$9.22K | ﹤0.01% | 5939 |
|
|
2022
Q3 | $139K | Sell |
395
-38
| -9% | -$17.6K | ﹤0.01% | 5908 |
|
|
2022
Q2 | $190K | Buy |
433
+86
| +25% | +$47.6K | ﹤0.01% | 5926 |
|
|
2022
Q1 | $263K | Buy |
347
+24
| +7% | +$19.7K | ﹤0.01% | 5778 |
|
|
2021
Q4 | $402K | Sell |
323
-33
| -9% | -$53.3K | ﹤0.01% | 5678 |
|
|
2021
Q3 | $718K | Buy |
356
+16
| +5% | +$34.4K | ﹤0.01% | 5282 |
|
|
2021
Q2 | $847K | Buy |
340
+223
| +191% | +$547K | ﹤0.01% | 5181 |
|
|
2021
Q1 | $290K | Sell |
117
-58
| -33% | -$172K | ﹤0.01% | 5444 |
|
|
2020
Q4 | $497K | Buy |
175
+70
| +67% | +$167K | ﹤0.01% | 5087 |
|
|
2020
Q3 | $249K | Buy |
105
+7
| +7% | +$17.3K | ﹤0.01% | 4992 |
|
|
2020
Q2 | $232K | Buy |
98
+7
| +8% | +$16.4K | ﹤0.01% | 5007 |
|
|
2020
Q1 | $184K | Sell |
91
-54
| -37% | -$138K | ﹤0.01% | 4896 |
|
|
2019
Q4 | $444K | Buy |
145
+41
| +39% | +$93.9K | ﹤0.01% | 4990 |
|
|
2019
Q3 | $253K | Buy |
104
+16
| +18% | +$43.8K | ﹤0.01% | 5016 |
|
|
2019
Q2 | $243K | Buy |
88
+18
| +26% | +$51.4K | ﹤0.01% | 4945 |
|
|
2019
Q1 | $179K | Sell |
70
-39
| -36% | -$110K | ﹤0.01% | 5122 |
|
|
2018
Q4 | $241K | Sell |
109
-1
| -0.9% | -$3.04K | ﹤0.01% | 5205 |
|
|
2018
Q3 | $492K | Buy |
110
+63
| +134% | +$315K | ﹤0.01% | 5015 |
|
|
2018
Q2 | $245K | Buy |
47
+36
| +327% | +$227K | ﹤0.01% | 5463 |
|
|
2018
Q1 | $93K | Buy |
+11
| New | +$93.7K | ﹤0.01% | 5724 |
|
Other funds holding MBIO
KAS
VFT
VCM
CG
TRCT
Morgan Stanley's MBIO Position: Q1 2026 in Review
Morgan Stanley reduced its Mustang Bio (MBIO) stake by 23% in Q1 2026, selling an estimated $33 and leaving 118 shares worth $86. The position accounts for ﹤0.01% of the portfolio, ranked #7830.
Morgan Stanley first reported a position in MBIO in Q1 2018 and has held it in 33 quarters since. The position peaked at $847K in Q2 2021. 22 funds tracked by Wall St. Rank hold MBIO as of Q1 2026.
- Morgan Stanley held 118 shares of Mustang Bio worth $86 as of Q1 2026.
- Morgan Stanley sold 35 Mustang Bio shares in Q1 2026, an estimated $33.
- Mustang Bio made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7830 holding.
- Morgan Stanley first reported a position in Mustang Bio in Q1 2018 and has held it in 33 quarters since.
- Morgan Stanley's Mustang Bio position peaked at $847K in Q2 2021.
- 22 funds tracked by Wall St. Rank held Mustang Bio as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.